Longeveron Inc. Overview
Pro stress-test →Longeveron Inc. is a clinical stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is laromestrocel (Lomecel-B™), derived from culture-expanded mesenchymal stem cells (MSCs) sourced from bone marrow of young healthy adult donors. The company is advancing pivotal clinical trials with multiple FDA designations aimed at addressing unmet medical needs in cardiology, neurology, and aging.
Strategic Profile
Pro stress-test →The company is focused on top-line Phase 2b HLHS results expected in Q3 2026; FDA guidance indicated a successful trial could serve as a pivotal study for a BLA. The company has obtained regulatory designations including Orphan Drug, Fast Track, Rare Pediatric Disease, and Regenerative Medicine Advanced Therapy (RMAT). Longeveron appointed Stephen H. Willard as CEO, effective February 11, 2026, replacing interim CEO Than Powell.
Competitive Landscape
Pro stress-test →Longeveron competes within the regenerative medicine and cell therapy space. The clinical-stage asset-light model faces competition from other MSC developers and broader cell therapy platforms. Its differentiation lies in multiple FDA designations (Orphan Drug, Fast Track, RMAT), ongoing Phase 2b pivotal trial in rare pediatric cardiology (HLHS), and published Phase 2a data showing neuroinflammation reduction in mild Alzheimer's disease. Market capitalizations in the cell therapy space vary widely; the company's ~$11.5M market cap reflects significant execution and regulatory risk.
Industry Context
Longeveron Inc. operates in Regenerative Medicine / Clinical-Stage Biotechnology.
Key facts
Founded: 2014 · Headquarters: Miami, Florida · Revenue: $2.4M · Market cap: $11.5M